Craig Hallum began coverage on shares of BioHarvest Sciences (NASDAQ:BHST - Free Report) in a report issued on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $15.00 price objective on the stock.
Separately, HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of BioHarvest Sciences in a research note on Tuesday, April 8th.
Check Out Our Latest Stock Report on BioHarvest Sciences
BioHarvest Sciences Stock Performance
Shares of NASDAQ:BHST traded up $0.08 during trading on Monday, hitting $6.47. 2,220 shares of the company's stock were exchanged, compared to its average volume of 18,183. The firm has a 50-day moving average of $5.96. The firm has a market capitalization of $106.27 million, a P/E ratio of -5.18 and a beta of 0.80. BioHarvest Sciences has a 52-week low of $6.34 and a 52-week high of $7.38.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The firm had revenue of $7.17 million for the quarter, compared to analysts' expectations of $7.24 million. Research analysts expect that BioHarvest Sciences will post -0.8 EPS for the current fiscal year.
Institutional Trading of BioHarvest Sciences
A hedge fund recently bought a new stake in BioHarvest Sciences stock. TD Waterhouse Canada Inc. acquired a new stake in shares of BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,042 shares of the company's stock, valued at approximately $69,000. TD Waterhouse Canada Inc. owned 0.07% of BioHarvest Sciences at the end of the most recent reporting period.
About BioHarvest Sciences
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Recommended Stories
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
